APOL1 expression leads to the loss of podocytes and, incidentally, renal function, and a recently initiated phase I trial (NCT04269031) is set to start evaluating the potential of anti-APOL1 ASO in treating CKD [77]. This evidence concerns the gene APOL1 and chronic kidney disease.